AGLE Aeglea Biotherapeutics Inc

Aeglea BioTherapeutics Inc is a biopharmaceutical company committed to developing enzyme-based therapeutics in the field of amino acid metabolism, which will transform the lives of patients with inborn errors of metabolism and cancer.

$0.42  -0.81 (-65.98%)
As of 11/30/2022 16:00:00 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  04/07/2016
Outstanding shares:  61,511,078
Average volume:  2,504,270
Market cap:   $75,043,515
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BYM7YF9
Valuation   (See tab for details)
PE ratio:   -0.35
PB ratio:   0.24
PS ratio:   14.99
Return on equity:   -116.81%
Net income %:   -1,438.65%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy